PACIRA BIOSCIENCES, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $726.4M | $701.0M | $675.0M | $666.8M | $541.5M | $429.6M | $421.0M |
| Cost of Revenue | — | $149.7M | $170.4M | $184.7M | $199.3M | $140.3M | $117.3M | $106.7M |
| Gross Profit | — | $576.7M | $530.5M | $490.3M | $467.5M | $401.3M | $312.3M | $314.3M |
| Gross Margin | — | 79.4% | 75.7% | 72.6% | 70.1% | 74.1% | 72.7% | 74.7% |
| Operating Expenses | ||||||||
| Research & Development | — | $117.3M | $81.6M | $76.3M | $84.8M | $55.5M | $59.4M | $72.1M |
| SG&A Expense | — | $368.8M | $294.1M | $269.4M | $254.5M | $199.3M | $193.5M | $200.8M |
| Operating Income | — | $19.2M | $-73.4M | $87.7M | $60.0M | $89.9M | $46.4M | $10.5M |
| Operating Margin | — | 2.6% | -10.5% | 13.0% | 9.0% | 16.6% | 10.8% | 2.5% |
| Interest Expense | — | $17.4M | $16.6M | $20.3M | $40.0M | $31.8M | $25.7M | $23.6M |
| Pretax Income | — | $16.9M | $-63.1M | $61.7M | $13.3M | $56.4M | $20.1M | $-10.7M |
| Income Tax Expense | — | $9.8M | $36.5M | $19.7M | $-2.6M | $14.4M | $-125.4M | $268.0K |
| Net Income | — | $7.0M | $-99.6M | $42.0M | $15.9M | $42.0M | $145.5M | $-11.0M |
| Net Margin | — | 1.0% | -14.2% | 6.2% | 2.4% | 7.8% | 33.9% | -2.6% |
| EPS (Basic) | — | $0.16 | $-2.15 | $0.91 | $0.35 | $0.95 | $3.41 | $-0.27 |
| EPS (Diluted) | — | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 | $3.33 | $-0.27 |
| Shares Outstanding (Basic) | 40.5M | 44.6M | 46.2M | 46.2M | 45.5M | 44.3M | 42.7M | 41.5M |
| Shares Outstanding (Diluted) | 40.5M | 45.0M | 46.2M | 52.0M | 46.5M | 45.6M | 43.7M | 41.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |